RDB05551 - pKM2L-pvCMV

Please review the QC test results indicated by check

icon below as well as clone information before placing your order.

pKM2L-pvCMV (#RDB05551)

Promoter Bank clone, CMV cytomegalovirus immediate enhancer/promoter (CMV) promoter

Alternative name	p1971-6F
Clone info.	The CMV cytomegalovirus immediate enhancer/promoter (CMV) promoter sequence (PCR-amplified ) was inserted into a Renilla luciferase reporter vector pKM2L (RDB04026).
Comment	Entire sequence of promoter region has not been confirmed.
Vector backbone	pKM2L (RDB04026) (Plasmid)
Size of vector backbone	4.2 kb
Selectable markers	Kan^r
Gene/insert name	CMV cytomegalovirus immediate enhancer/promoter (CMV) genomic DNA
Depositor\|Developer	DNA Bank, \|

Sequence	RDB05551z.seq

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.

Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Please visit Information of Request for Distribution.[link]

Terms and conditions for distribution 1. The RECIPIENT agrees to use the BIOLOGICAL RESOURCE only for academic research in the non-profit organization. 2. In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
Additional terms and conditions:
The use of the BIOLOGICAL RESOURCE is restricted to the academic researches conducted by non-profit organization. By using this material, the RECIPIENT agrees to be bound by the conditions of the limited use statement of the Promega Corporation.

提供案内 (日本国内) [open/close]

Ordering forms	Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ] MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ] Please visit Information of Request for Distribution.[link]
Terms and conditions for distribution	1. The RECIPIENT agrees to use the BIOLOGICAL RESOURCE only for academic research in the non-profit organization. 2. In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. Additional terms and conditions: The use of the BIOLOGICAL RESOURCE is restricted to the academic researches conducted by non-profit organization. By using this material, the RECIPIENT agrees to be bound by the conditions of the limited use statement of the Promega Corporation.

必要書類	提供依頼書 [依頼書の記入例 ] 提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ] 手続きの概要は、「提供申込みについて[link]」をご覧ください。
MTAに書く使用条件	1. 本件リソースは学術研究機関にのみ提供し、学術研究にのみ利用することができる。　2. 謝辞の表明を必要とする。 MTAに書く付加的使用条件：本件リソースの使用は学術機関での学術研究に限る。本件リソースの使用にあたって、利用者はプロメガ社の限定使用条件に従う必要がある。

Catalog #	Resource name	Shipping form	Fee (non-profit org.)
RDB05551	pKM2L-pvCMV	DNA solution

Please review the QC test results indicated by check

icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The pKM2L-pvCMV was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB05551).

Reference section:

Further references such as user reports and related articles (go to bottom)

QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet	RDB12815_A4G3p1-2.pdf

Nucleotide sequence of a portion of this resource (if available).

Primer: phRLR2primer (Pr0083) Region: Intron, CMV en_pro Sequence file: RDB12815_A4G3d.seq
>05551_12815_A4G3_phRLR2_E01_13.ab1 1 AACTTCCGGT CTCGACAGCC CAGTTTCTAT TGGTCTCCTT AAACCTGTCT TGTAACCTTG 61 ATACTTACCT GCCCAGTGCC TCACGACCAA CTTCTGCAGT ACCCGGGTGA ATTCTACGCG 121 TCGACAGGCC ACTGACTGCG TTAGCAATTT AACTGTGATA AACTACCGCA ATAAAGCTTC 181 TAGTGATCTG ACGGTTCACT AAACGAGCTC TGCTTATATA GACCTCCCAC CGTACACGCC 241 TACCGCCCAT TTGCGTCAAC GGGGCGGGGT TATTACGACA TTTTGGAAAG TCCCGTTGAT 301 TTTGGTGCCA AAACAAACTC CCATTGACGT CAATGGGGTG GAGACTTGGA AATCCCCGTG 361 AGTCAAACCG CTATCCACGC CCATTGGTGT ACTGCCAAAA CCGCATCACC ATGGTAATAG 421 CGATGACTAA TACGTAGATG TACTGCCAAG TAGGAAAGTC CCGTAAGGTC ATGTACTGGG 481 CATAATGCCA GGCGGGCCAT TTACCGTCAT TGACGTCAAT AGGGGGCGGA CTTGGCATAT 541 GATACACTTG ATGTACTGCC AAGTGGGCAG TTTACCGTAA ATACTCCACC CATTGACGTC 601 AATGGAAAGT CCCTATTGGC GTTACTATGG GAACATACGT CATTATTGAC GTCAATGGGC 661 GGGGGTCGTT GGGCGGTCAG CCAGGCGGGC CATTTACCGT AAGTTATGTA ACGCGGAACT 721 CCATATATGG GCTATGAACT AATGACCCCG TAATTGATTA CTATTAATAA CTAGTCAATA 781 ATCAATGCCA ACATGGCGGT CATATTGGAC ATGAGCCAAT ATAAATGTAC ATATTATGAT 841 ATAGATACAA CGTATGCAAT GGCCAATAGC CAATATTGAT TTATGCTATA TAACCAATGA 901 ATAATATGGC TAATGGCCAA TATTGAGCCA CTAGTGCATG CATATGTGAA GCTTAGAGCT 961 CGAGATCTTA ATCATTACCC TGTTTATCCC TATTTAAATG ACCTGCAGGC ATGCAAAGCT 1021 TTGGCACTGG GCCGTCGTTT TTACACCGGT CGTTGACTGG TAAAACCCCT GACGTACCGA 1081 CTAGTTCGTC TTGCAGCACA TTCCCCCATT TTTCG //
Primer: pAxCALNLF1 (Pr0166) Region: hRluc Sequence file: RDB12815_A4G3e.seq
>05551_12815_A4G3_pAxCALNLF1_D01_10.ab1 1 ATCAATTATC TTATCATGTC TGCTCGAAGC GGCCGCTCTA GAATTACTGC TCGTTCTTCA 61 GCACGCGCTC CACGAAGCTC TTGATGTACT TACCCATTTC ATCTGGAGCG TCCTCCTGGC 121 TGAAGTGGAG GCCCTTCACC TTCACGAACT CGGTGTTAGG GAACTTCTTA GCTCCCTCGA 181 CAATAGCGTT GGAAAAGAAC CCAGGGTCGG ACTCGATGAA CATCTTAGGC AGATCGTCGC 241 TGGCCCGAAG GTAGGCGTTG TAGTTGCGGA CAATCTGGAC GACGTCGGGC TTGCCTCCCT 301 TAACGAGAGG GATCTCGCGA GGCCAGGAGA GGGTAGGCCG TCTAACCTCG CCCTTCTCCT 361 TGAATGGCTC CAGGTAGGCA GCGAACTCCT CAGGCTCCAG TTTCCGCATG ATCTTGCTTG 421 GGAGCATGGT CTCGACGAAG AAGTTATTCT CAAGCACCAT TTTCTCGCCC TCTTCGCTCT 481 TGATCAGGGC GATATCCTCC TCGATGTCAG GCCACTCGTC CCAGGACTCG ATCACGTCCA 541 CGACACTCTC AGCATGGACG ATGGCCTTGA TCTTGTCTTG GTGCTCGTAG GAGTAGTGAA 601 AGGCCAGACA AGCCCCCCAG TCGTGGCCCA CAAAGATGAT TTTCTTTGGA AGGTTCAGCA 661 GCTCGAACCA AGCGGTGAGG TACTTGTAGT GATCCAGGAG GCGATATGAG CCATTCCCGC 721 TCTTGCCGGA CTTACCCATT CCGATCAGAT CAGGGATGAT GCATCTAGCC ACGGGCTCGA 781 TGTGAGGCAC GACGTGCCTC CACAGGTAGC TGGAGGCAGC GTTACCATGC AGAAAAATCA 841 CGGCGTTCTC GGCGTGCTTC TCGGAATCAT AGTAGTTGAT GAACGAAGTC CAGCACGTTC 901 ATTTGCTTGC AGCGAGCCCA CCACTGAGGC CCAGTGATCA TGCGTTTGCG TTGCTCGGGG 961 TCGTACACCT TTGGAAAGCC ATGGTGGGCT AGCCCTATAG TGAGTCGTTA TTAAGTAACT 1021 TCTAGCCTTT AGAGCTGTAA TTGAACTTGG GAGTGAACAC CTGTGAAGAG AAAGGCTAAG 1081 TGGATGTCAG TAAGAACCAT AGGGTGCCCA TTATTCCAG //
Primer: M13_-40 (Pr0410) Region: CMV en_pro, intron Sequence file: RDB12815_A4G3f.seq
>05551_12815_A4G3_M13_(-40)_C01_07.ab1 1 CCGGCCGGCC AGCTTGCATG CCTGCAGGTC ATTTAAATAG GGATAACAGG GTAATGATTA 61 AGATCTCGAG CTCTAAGCTT CACATATGCA TGCACTAGTG GCTCAATATT GGCCATTAGC 121 CATATTATTC ATTGGTTATA TAGCATAAAT CAATATTGGC TATTGGCCAT TGCATACGTT 181 GTATCTATAT CATAATATGT ACATTTATAT TGGCTCATGT CCAATATGAC CGCCATGTTG 241 GCATTGATTA TTGACTAGTT ATTAATAGTA ATCAATTACG GGGTCATTAG TTCATAGCCC 301 ATATATGGAG TTCCGCGTTA CATAACTTAC GGTAAATGGC CCGCCTGGCT GACCGCCCAA 361 CGACCCCCGC CCATTGACGT CAATAATGAC GTATGTTCCC ATAGTAACGC CAATAGGGAC 421 TTTCCATTGA CGTCAATGGG TGGAGTATTT ACGGTAAACT GCCCACTTGG CAGTACATCA 481 AGTGTATCAT ATGCCAAGTC CGCCCCCTAT TGACGTCAAT GACGGTAAAT GGCCCGCCTG 541 GCATTATGCC CAGTACATGA CCTTACGGGA CTTTCCTACT TGGCAGTACA TCTACGTATT 601 AGTCATCGCT ATTACCATGG TGATGCGGTT TTGGCAGTAC ACCAATGGGC GTGGATAGCG 661 GTTTGACTCA CGGGGATTTC CAAGTCTCCA CCCCATTGAC GTCAATGGGA GTTTGTTTTG 721 GCACCAAAAT CAACGGGACT TTCCAAAATG TCGTAATAAC CCCGCCCCGT TGACGCAAAT 781 GGGCGGTAGG CGTGTACGGT GGGAGGTCTA TATAAGCAGA GCTCGTTTAG TGAACCGTCA 841 GATCACTAGA AGCTTTATTG CGGTAGTTTA TCACAGTTAA ATTGCTAACG CAGTCAGTGG 901 CCTGTCGACG CGTAGAATTC ACCCGGGTAC TGCAGAAGTT GGTCGTGAGG CACTGGGCAG 961 GTAAGTATCA AAGGTTACAA GACAGGTTTA AAGGAGACCC AATAGAAACT GGGCTTTGTC 1021 GAGACAGAGA GACTCTTTGC GTTTCTGATA GGCACCTATT GGATCCTAAC TGGACATTCA 1081 ACTTTGGCCG TTTCTTCTCC AACAAGGGGG TGTTGCA //
Primer: CSII_CMV5_v2 (Pr0255) Region: CMV en_pro, intron, hRluc Sequence file: RDB12815_A4G3g.seq
>05551_12815_B0AfF_CSII-CMV_5v2_H05_08_ABI08.ab1 1 NNNNNNNNNN NNNNNNGTTN NTCNCNGTTA AATTGCTAAC GCAGTCNGTG GCCTGTCGAC 61 GCGTAGAATT CACCCGGGTA CTGCAGAAGT TGGTCGTGAG GCACTGGGCA GGTAAGTATC 121 AAGGTTACAA GACAGGTTTA AGGAGACCAA TAGAAACTGG GCTTGTCGAG ACAGAGAAGA 181 CTCTTGCGTT TCTGATAGGC ACCTATTGGT CTTACTGACA TCCACTTTGC CTTTCTCTCC 241 ACAGGTGTCC ACTCCCAGTT CAATTACAGC TCTTAAGGCT AGAGTACTTA ATACGACTCA 301 CTATAGGCTA GCCACCATGG CTTCCAAGGT GTACGACCCC GAGCAACGCA AACGCATGAT 361 CACTGGGCCT CAGTGGTGGG CTCGCTGCAA GCAAATGAAC GTGCTGGACT CCTTCATCAA 421 CTACTATGAT TCCGAGAAGC ACGCCGAGAA CGCCGTGATT TTTCTGCATG GTAACGCTGC 481 CTCCAGCTAC CTGTGGAGGC ACGTCGTGCC TCACATCGAG CCCGTGGCTA GATGCATCAT 541 CCCTGATCTG ATCGGAATGG GTAAGTCCGG CAAGAGCGGG AATGGCTCAT ATCGCCTCCT 601 GGATCACTAC AAGTACCTCA CCGCTTGGTT CGAGCTGCTG AACCTTCCAA AGAAAATCAT 661 CTTTGTGGGC CACGACTGGG GGGCTTGTCT GGCCTTTCAC TACTCCTACG AGCACCAAGA 721 CAAGATCAAG GCCATCGTCC ATGCTGAGAG TGTCGTGGAC GTGATCGAGT CCTGGGANGA 781 GTGGNCTGAC ATCGAGGANG ANATCGCCCT GATCNAGANC GAANANGGCG ANAAAATGGT 841 GCTTGANAAT AACTTCTTCN TCNANANCAT GCTCCCNANC AAGATCATGC GGAAANNGGA 901 NNNNGANGAN TTCNCTGNCN ANCNGNNNCC NTTCNNNGAN ANNNNNGNNN TNANANNGNC 961 NANCNNNNNN NNNN //

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles

user_report	Kakimoto, M., Spermine synthesis inhibitor blocks 25-hydroxycholesterol-induced- apoptosis via SREBP2 upregulation in DLD-1 cell spheroids. Biochem .Biophys. Rep. 22: 100754 (2020). PMID 32258442. [link to RRC of NBRP]

Resource search

Link

Other resources in our bank

External Database
CMV cytomegalovirus immediate enhancer/promoter (CMV)

Reference sequence